Connor Clark & Lunn Investment Management Ltd. Grows Stake in Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX) by 62.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 359,197 shares of the company’s stock after buying an additional 138,510 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned 0.37% of Poseida Therapeutics worth $1,027,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Renaissance Technologies LLC increased its position in Poseida Therapeutics by 53.4% during the second quarter. Renaissance Technologies LLC now owns 854,900 shares of the company’s stock worth $2,496,000 after buying an additional 297,500 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Poseida Therapeutics by 16.3% in the first quarter. Vanguard Group Inc. now owns 3,373,065 shares of the company’s stock valued at $10,760,000 after purchasing an additional 473,746 shares during the period. Public Employees Retirement System of Ohio grew its position in shares of Poseida Therapeutics by 177.3% in the first quarter. Public Employees Retirement System of Ohio now owns 62,945 shares of the company’s stock valued at $201,000 after purchasing an additional 40,245 shares during the period. Lazard Asset Management LLC grew its position in shares of Poseida Therapeutics by 280.3% in the first quarter. Lazard Asset Management LLC now owns 28,679 shares of the company’s stock valued at $91,000 after purchasing an additional 21,138 shares during the period. Finally, Bayesian Capital Management LP purchased a new stake in shares of Poseida Therapeutics in the first quarter valued at $33,000. Hedge funds and other institutional investors own 46.87% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. BTIG Research reiterated a “neutral” rating on shares of Poseida Therapeutics in a report on Tuesday. HC Wainwright restated a “neutral” rating and set a $9.00 price objective (down previously from $20.00) on shares of Poseida Therapeutics in a research note on Tuesday. Cantor Fitzgerald cut Poseida Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. Finally, William Blair restated a “market perform” rating on shares of Poseida Therapeutics in a research note on Tuesday. Four analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, Poseida Therapeutics currently has a consensus rating of “Hold” and an average price target of $9.50.

Poseida Therapeutics Stock Down 0.5 %

Shares of Poseida Therapeutics stock opened at $9.33 on Thursday. The company has a quick ratio of 3.20, a current ratio of 3.20 and a debt-to-equity ratio of 0.68. The firm has a market cap of $909.35 million, a P/E ratio of -14.81 and a beta of 0.54. Poseida Therapeutics, Inc. has a fifty-two week low of $1.87 and a fifty-two week high of $9.42. The business has a 50-day moving average price of $3.02 and a 200 day moving average price of $3.01.

Insider Activity at Poseida Therapeutics

In related news, Chairman Mark J. Gergen sold 30,000 shares of the business’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $9.27, for a total value of $278,100.00. Following the completion of the sale, the chairman now directly owns 651,291 shares of the company’s stock, valued at $6,037,467.57. The trade was a 4.40 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 2.90% of the stock is owned by corporate insiders.

About Poseida Therapeutics

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.